1. Home
  2. EDIT vs OPP Comparison

EDIT vs OPP Comparison

Compare EDIT & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • OPP
  • Stock Information
  • Founded
  • EDIT 2013
  • OPP 2010
  • Country
  • EDIT United States
  • OPP United States
  • Employees
  • EDIT N/A
  • OPP N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • OPP Finance/Investors Services
  • Sector
  • EDIT Health Care
  • OPP Finance
  • Exchange
  • EDIT Nasdaq
  • OPP Nasdaq
  • Market Cap
  • EDIT 179.1M
  • OPP 199.8M
  • IPO Year
  • EDIT 2016
  • OPP N/A
  • Fundamental
  • Price
  • EDIT $2.75
  • OPP $8.47
  • Analyst Decision
  • EDIT Buy
  • OPP
  • Analyst Count
  • EDIT 12
  • OPP 0
  • Target Price
  • EDIT $6.20
  • OPP N/A
  • AVG Volume (30 Days)
  • EDIT 3.3M
  • OPP 108.0K
  • Earning Date
  • EDIT 08-06-2025
  • OPP 01-01-0001
  • Dividend Yield
  • EDIT N/A
  • OPP 14.41%
  • EPS Growth
  • EDIT N/A
  • OPP N/A
  • EPS
  • EDIT N/A
  • OPP N/A
  • Revenue
  • EDIT $35,837,000.00
  • OPP N/A
  • Revenue This Year
  • EDIT N/A
  • OPP N/A
  • Revenue Next Year
  • EDIT N/A
  • OPP N/A
  • P/E Ratio
  • EDIT N/A
  • OPP N/A
  • Revenue Growth
  • EDIT N/A
  • OPP N/A
  • 52 Week Low
  • EDIT $0.91
  • OPP $7.26
  • 52 Week High
  • EDIT $6.05
  • OPP $8.83
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 61.68
  • OPP 59.68
  • Support Level
  • EDIT $2.48
  • OPP $8.44
  • Resistance Level
  • EDIT $3.24
  • OPP $8.57
  • Average True Range (ATR)
  • EDIT 0.26
  • OPP 0.06
  • MACD
  • EDIT 0.02
  • OPP 0.00
  • Stochastic Oscillator
  • EDIT 57.94
  • OPP 76.19

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.

Share on Social Networks: